GGGabriela Beatriz Gomez

Gabriela Beatriz Gomez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gabriela Beatriz Gomez has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PA-512 Behavioural predictors of uptake of HIV and pregnancy prevention products among adolescent girls and young women and female sex workers in Kenya and Uganda

    by Yvonne Wangui Machira, Lang Gao, Edel Koki, Josphat Korir, Stephanie Shari, Omu Anzala, Gloria Omosa-Manyonyi, Mitzy Gafos, Pitchaya Indravudh, Kenneth Katumba, et al.

    Background UPTAKE is a programme to accelerate access and facilitate adherence to effective and innovative long-acting technologies to prevent HIV and unintended pregnancy among Adolescent Girls and Young Women (AGYW) and Female Sex Workers (FSW) through behavioural science in Kenya and Uganda. We identified characteristics which predict the use of HIV and pregnancy prevention products and measured the strength of preferences. Methods A quantitative survey was administered to 326 AGYW and 334 FSW in both countries. Descriptive, inferential, and segmentation analysis was applied to reveal user-preferences, behavioural patterns and the predicting factors of product uptake. Results Product usage, particularly for HIV prevention, was lower among AGYW than FSW. Although awareness of long-acting prevention products including implants and intra-uterine devices (IUDs) was high among both groups, uptake remained low, primarily due to perceived side effects. For pregnancy prevention, the male condom was most used among both AGYW and FSW, followed by injectables. For HIV prevention, male condoms were most used, followed by oral pre-exposure prophylaxis (PrEP). Effectiveness and easy accessibility were the most highly valued product features. The influential factors driving and predicting uptake varied by product. At the 0.05 significance level, risk preference, stigma, Intimate Partner Violence (IPV), locus of control, peer influence, subjective risk, country, and age appeared significant in influencing uptake of various products. Segmentation was only found influential for the uptake of implants and male condoms among AGYW. Conclusion More than half of participants are aware of long-acting contraceptive products, though only 17% of AGYW and 22% of FSW used implants, and less than 2% used IUDs. Furthermore, very few recognised the ring as a HIV prevention method, and none used it. Behavioural interventions should be tailored by product and respond to the key influential factors to increase awareness and bridge the gap between awareness and uptake.


  • Open Access

    Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States

    by Gabriela B Gomez, Christopher B Nelson, Christopher Rizzo, Donald S Shepard, Sandra S Chaves

    The target populations and financing mechanisms for a new health technology may affect health inequalities in access and impact. We projected the distributional consequences of introducing nirsevimab for prevention of respiratory syncytial virus in a US birth cohort of infants through alternative reimbursement pathway scenarios. Using the RSV immunization impact model, we estimated that a vaccine-like reimbursement pathway would cover 32% more infants than a pharmaceutical pathway. The vaccine pathway would avert 30% more hospitalizations and 39% more emergency room visits overall, and 44% and 44%, respectively, in publicly insured infants. The vaccine pathway would benefit infants from poorer households.


  • Open Access

    Updating age-specific contact structures to match evolving demography in a dynamic mathematical model of tuberculosis vaccination

    by Chathika Krishan Weerasuriya, Rebecca Claire Harris, Christopher Finn McQuaid, Gabriela B. Gomez, Richard G. White

    We investigated the effects of updating age-specific social contact matrices to match evolving demography on vaccine impact estimates. We used a dynamic transmission model of tuberculosis in India as a case study. We modelled four incremental methods to update contact matrices over time, where each method incorporated its predecessor: fixed contact matrix (M0), preserved contact reciprocity (M1), preserved contact assortativity (M2), and preserved average contacts per individual (M3). We updated the contact matrices of a deterministic compartmental model of tuberculosis transmission, calibrated to epidemiologic data between 2000 and 2019 derived from India. We additionally calibrated the M0, M2, and M3 models to the 2050 TB incidence rate projected by the calibrated M1 model. We stratified age into three groups, children (E-like tuberculosis vaccine delivered from 2027 and estimated the per cent TB incidence rate reduction (IRR) in 2050 under each update method. We found that vaccine impact estimates in all age groups remained relatively stable between the M0–M3 models, irrespective of vaccine-targeting by age group. The maximum difference in impact, observed following adult-targeted vaccination, was 7% in the elderly, in whom we observed IRRs of 19% (uncertainty range 13–32), 20% (UR 13–31), 22% (UR 14–37), and 26% (UR 18–38) following M0, M1, M2 and M3 updates, respectively. We found that model-based TB vaccine impact estimates were relatively insensitive to demography-matched contact matrix updates in an India-like demographic and epidemiologic scenario. Current model-based TB vaccine impact estimates may be reasonably robust to the lack of contact matrix updates, but further research is needed to confirm and generalise this finding.


  • Open Access

    Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

    by Gabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, Norbert Ndjeka, Anna Marie Celina Garfin, Nino Lomtadze, Zaza Avaliani, Nana Kiria, Shelly Malhotra, Sarah Cook-Scalise, et al.

    Objectives Patients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in three epidemiological settings. Design Cost-effectiveness analysis using Markov cohort model. Setting South Africa, Georgia and the Philippines. Participants XDR-TB and multidrug-resistant tuberculosis (MDR-TB) failure and treatment intolerant patients. Interventions BPaL regimen. Primary and secondary outcome measures (1) Incremental cost per disability-adjusted life years averted by using BPaL against standard of care at the Global Drug Facility list price. (2) The potential maximum price at which the BPaL regimen could become cost neutral. Results BPaL for XDR-TB is likely to be cost saving in all study settings when pretomanid is priced at the Global Drug Facility list price. The magnitude of these savings depends on the prevalence of XDR-TB in the country and can amount, over 5 years, to approximately US$ 3 million in South Africa, US$ 200 000 and US$ 60 000 in Georgia and the Philippines, respectively. In South Africa, related future costs of antiretroviral treatment (ART) due to survival of more patients following treatment with BPaL reduced the magnitude of expected savings to approximately US$ 1 million. Overall, when BPaL is introduced to a wider population, including MDR-TB treatment failure and treatment intolerant, we observe increased savings and clinical benefits. The potential threshold price at which the probability of the introduction of BPaL becoming cost neutral begins to increase is higher in Georgia and the Philippines (US$ 3650 and US$ 3800, respectively) compared with South Africa (US$ 500) including ART costs. Conclusions Our results estimate that BPaL can be a cost-saving addition to the local TB programmes in varied programmatic settings.


  • Open Access

    The Shinyanga Patient: A Patient’s Journey through HIV Treatment Cascade in Rural Tanzania

    by Nwanneka E Okere, Veryeh Sambu, Yudas Ndungile, Eric van Praag, Sabine Hermans, Denise Naniche, Tobias F Rinke de Wit, Werner Maokola, Gabriela B Gomez

    The 2016–2017 Tanzania HIV Impact Survey (THIS) reported the accomplishments towards the 90-90-90 global HIV targets at 61-94-87, affirming the need to focus on the first 90 (i.e., getting 90% of people living with HIV (PLHIV) tested). We conducted a patient-pathway analysis to understand the gap observed, by assessing the alignment between where PLHIV seek healthcare and where HIV services are available in the Shinyanga region, Tanzania. We used existing and publicly available data from the National AIDS Control program, national surveys, registries, and relevant national reports. Region-wide, the majority (n = 458/722, 64%) of THIS respondents accessed their last HIV test at public sector facilities. There were 65.9%, 45.1%, and 74.1% who could also access antiretroviral therapy (ART), CD4 testing, and HIV viral load testing at the location of their last HIV test, respectively. In 2019, the viral suppression rate estimated among PLHIV on ART in the Shinyanga region was 91.5%. PLHIV access HIV testing mostly in public health facilities; our research shows that synergies can be achieved to improve access to services further down the cascade in this sector. Furthermore, effective engagement with the private sector (not-for-profit and for-profit) will help to achieve the last mile toward ending the HIV epidemic.


  • Open Access

    Exploring Sustainability in the Era of Differentiated HIV Service Delivery in Sub-Saharan Africa: A Systematic Review

    by Nwanneka E. Msc Okere, Laura Lennox, Lisa Bsc Urlings, Nathan Ford, Denise Naniche, Tobias F. Rinke de Wit, Sabine Hermans, Gabriela B. Gomez

    Introduction: The World Health Organization recommends differentiated service delivery (DSD) to support resource-limited health systems in providing patient-centered HIV care. DSD offers alternative care models to clinic-based care for people living with HIV who are stable on antiretroviral therapy (ART). Despite good patient-related outcomes, there is limited evidence of their sustainability. Our review evaluated the reporting of sustainability indicators of DSD interventions conducted in sub-Saharan Africa (SSA). Methods: We searched PubMed and EMBASE for studies conducted between 2000 and 2019 assessing DSD interventions targeting HIV-positive individuals who are established in ART in sub-Saharan Africa. We evaluated them through a comprehensive sustainability framework of constructs categorized into 6 domains (intervention design, process, external environment, resources, organizational setting, and people involvement). We scored each construct 1, 2, or 3 for no, partial, or sufficient level of evidence, respectively. Interventions with a calculated sustainability score (overall and domain-specific) of >90% or domain-specific median score >2.7 were considered likely to be sustainable. Results: Overall scores ranged from 69% to 98%. Top scoring intervention types included adherence clubs (98%) and community ART groups (95%) which comprised more than half of interventions. The highest scoring domains were design (2.9) and organizational setting (2.8). The domains of resources (2.4) and people involvement (2.3) scored lowest revealing potential areas for improvement to support DSD sustainability. Conclusions: With the right investment in stakeholder involvement and domestic funding, DSD models generally show potential for sustainability. Our results could guide informed decisions on which DSD intervention is likely to be sustainable per setting and highlight areas that could motivate further research.


  • Open Access

    Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study

    by Laurent Coudeville, Ombeline Jollivet, Cedric Mahé, Sandra Chaves, Gabriela B. Gomez

    Background: The accelerated vaccine development in response to the COVID-19 pandemic should lead to a vaccine being available early 2021, albeit in limited supply and possibly without full vaccine acceptance. We assessed the short-term impact of a COVID-19 immunization program with varying constraints on population health and non-pharmaceutical interventions (NPIs) needs. Methods: A SARS-CoV-2 transmission model was calibrated to French epidemiological data. We defined several vaccine implementation scenarios starting in January 2021 based on timing of discontinuation of NPIs, supply and uptake constraints, and their relaxation. We assessed the number of COVID-19 hospitalizations averted, the need for and number of days with NPIs in place over the 2021–2022 period. Results: An immunisation program under constraints could reduce the burden of COVID-19 hospitalizations by 9–40% if the vaccine prevents against infections. Relaxation of constraints not only reduces further COVID-19 hospitalizations (30–39% incremental reduction), it also allows for NPIs to be discontinued post-2021 (0 days with NPIs in 2022 versus 11 to 125 days for vaccination programs under constraints and 327 in the absence of vaccination). Conclusion: For 2021, COVID-19 control is expected to rely on a combination of NPIs and the outcome of early immunisation programs. The ability to overcome supply and uptake constraints will help prevent the need for further NPIs post-2021. As the programs expand, efficiency assessments will be needed to ensure optimisation of control policies post-emergency use.


  • Open Access

    Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis

    by Chathika Krishan Weerasuriya, Rebecca Claire Harris, Matthew Quaife, Christopher Finn McQuaid, Richard G. White, Gabriela B. Gomez

    New tuberculosis vaccines have made substantial progress in the development pipeline. Previous modelling suggests that adolescent/adult mass vaccination may cost-effectively contribute towards achieving global tuberculosis control goals. These analyses have not considered the budgetary feasibility of vaccine programmes. We estimate the maximum total cost that the public health sectors in India and China should expect to pay to introduce a M72/AS01E-like vaccine deemed cost-effective at country-specific willingness to pay thresholds for cost-effectiveness. To estimate the total disability adjusted life years (DALYs) averted by the vaccination programme, we simulated a 50% efficacy vaccine providing 10-years of protection in post-infection populations between 2027 and 2050 in India and China using a dynamic transmission model of M. tuberculosis. We investigated two mass vaccination strategies, both delivered every 10-years achieving 70% coverage: Vaccinating adults and adolescents (age ≥10y), or only the most efficient 10-year age subgroup (defined as greatest DALYs averted per vaccine given). We used country-specific thresholds for cost-effectiveness to estimate the maximum total cost (Cmax) a government should be willing to pay for each vaccination strategy. Adult/adolescent vaccination resulted in a Cmax of $21 billion (uncertainty interval [UI]: 16–27) in India, and $15B (UI:12–29) in China at willingness to pay thresholds of $264/DALY averted and $3650/DALY averted, respectively. Vaccinating the highest efficiency age group (India: 50–59y; China: 60–69y) resulted in a Cmax of $5B (UI:4–6) in India and $6B (UI:4–7) in China. Mass vaccination against tuberculosis of all adults and adolescents, deemed cost-effective, will likely impose a substantial budgetary burden. Targeted tuberculosis vaccination, deemed cost-effective, may represent a more affordable approach.


  • Estimating Cost Functions for Resource Allocation Using Transmission Models: A Case Study of Tuberculosis Case Finding in South Africa

    by Gabriela B. Gomez, Don L. Mudzengi, Fiammetta Bozzani, Nicholas A. Menzies, Anna Vassall